Cytosorbents Announces Expiration of Series B Warrants

An update from Cytosorbents ( (CTSO) ) is now available.

On June 11, 2025, CytoSorbents Corporation announced that the 5-day volume weighted average price per share of its common stock was below the required minimum of $2.00, leading to the expiration of the Series B Right Warrants issued in a prior Rights Offering. Consequently, payments made for the exercise of these warrants will be refunded without interest or penalty.

The most recent analyst rating on (CTSO) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Cytosorbents stock, see the CTSO Stock Forecast page.

Spark’s Take on CTSO Stock

According to Spark, TipRanks’ AI Analyst, CTSO is a Neutral.

Cytosorbents’ overall stock score is primarily influenced by its challenging financial performance, marked by declining revenues and high leverage. While technical analysis and recent corporate events show some positive signs, the negative valuation metrics and mixed earnings call sentiment reflect ongoing operational and market challenges.

To see Spark’s full report on CTSO stock, click here.

More about Cytosorbents

Average Trading Volume: 100,606

Technical Sentiment Signal: Hold

Current Market Cap: $66.37M

For a thorough assessment of CTSO stock, go to TipRanks’ Stock Analysis page.